Logo image of KZR

KEZAR LIFE SCIENCES INC (KZR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KZR - US49372L2097 - Common Stock

6.2 USD
0 (0%)
Last: 11/28/2025, 7:43:10 PM
Fundamental Rating

2

Overall KZR gets a fundamental rating of 2 out of 10. We evaluated KZR against 533 industry peers in the Biotechnology industry. The financial health of KZR is average, but there are quite some concerns on its profitability. KZR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KZR has reported negative net income.
In the past year KZR has reported a negative cash flow from operations.
KZR had negative earnings in each of the past 5 years.
KZR had a negative operating cash flow in each of the past 5 years.
KZR Yearly Net Income VS EBIT VS OCF VS FCFKZR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

KZR has a Return On Assets of -65.55%. This is comparable to the rest of the industry: KZR outperforms 40.71% of its industry peers.
KZR has a Return On Equity (-77.93%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.55%
ROE -77.93%
ROIC N/A
ROA(3y)-42.23%
ROA(5y)-35.85%
ROE(3y)-50.4%
ROE(5y)-41.71%
ROIC(3y)N/A
ROIC(5y)N/A
KZR Yearly ROA, ROE, ROICKZR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

KZR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KZR Yearly Profit, Operating, Gross MarginsKZR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

KZR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KZR has more shares outstanding
KZR has less shares outstanding than it did 5 years ago.
The debt/assets ratio for KZR is higher compared to a year ago.
KZR Yearly Shares OutstandingKZR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
KZR Yearly Total Debt VS Total AssetsKZR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

KZR has an Altman-Z score of -5.71. This is a bad value and indicates that KZR is not financially healthy and even has some risk of bankruptcy.
KZR has a Altman-Z score of -5.71. This is in the lower half of the industry: KZR underperforms 63.04% of its industry peers.
KZR has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of KZR (0.03) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -5.71
ROIC/WACCN/A
WACC9.48%
KZR Yearly LT Debt VS Equity VS FCFKZR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.29 indicates that KZR has no problem at all paying its short term obligations.
The Current ratio of KZR (7.29) is better than 71.48% of its industry peers.
A Quick Ratio of 7.29 indicates that KZR has no problem at all paying its short term obligations.
KZR has a better Quick ratio (7.29) than 71.86% of its industry peers.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 7.29
KZR Yearly Current Assets VS Current LiabilitesKZR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.38% over the past year.
Looking at the last year, KZR shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)5.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.96%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.02% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.5%
EPS Next 2Y23.1%
EPS Next 3Y15.67%
EPS Next 5Y13.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KZR Yearly Revenue VS EstimatesKZR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2029 2030 2031 2032 50M 100M 150M 200M 250M
KZR Yearly EPS VS EstimatesKZR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KZR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KZR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KZR Price Earnings VS Forward Price EarningsKZR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KZR Per share dataKZR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as KZR's earnings are expected to grow with 15.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.1%
EPS Next 3Y15.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KZR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEZAR LIFE SCIENCES INC

NASDAQ:KZR (11/28/2025, 7:43:10 PM)

6.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-23 2026-03-23/amc
Inst Owners61.32%
Inst Owner Change-6.01%
Ins Owners2.15%
Ins Owner Change-0.01%
Market Cap45.38M
Revenue(TTM)N/A
Net Income(TTM)-71.53M
Analysts70
Price Target6.12 (-1.29%)
Short Float %4.95%
Short Ratio1.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.11%
Min EPS beat(2)13.72%
Max EPS beat(2)22.49%
EPS beat(4)4
Avg EPS beat(4)13.44%
Min EPS beat(4)4.91%
Max EPS beat(4)22.49%
EPS beat(8)7
Avg EPS beat(8)9.45%
EPS beat(12)9
Avg EPS beat(12)6.9%
EPS beat(16)12
Avg EPS beat(16)7.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-52%
PT rev (3m)-52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.89%
EPS NY rev (1m)0%
EPS NY rev (3m)3.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB 0.49
EV/EBITDA N/A
EPS(TTM)-8.44
EYN/A
EPS(NY)-5.45
Fwd EYN/A
FCF(TTM)-8.78
FCFYN/A
OCF(TTM)-8.77
OCFYN/A
SpS0
BVpS12.54
TBVpS12.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.55%
ROE -77.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.23%
ROA(5y)-35.85%
ROE(3y)-50.4%
ROE(5y)-41.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 7.29
Altman-Z -5.71
F-Score2
WACC9.48%
ROIC/WACCN/A
Cap/Depr(3y)109.16%
Cap/Depr(5y)72.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.96%
EPS Next Y26.5%
EPS Next 2Y23.1%
EPS Next 3Y15.67%
EPS Next 5Y13.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.07%
OCF growth 3YN/A
OCF growth 5YN/A

KEZAR LIFE SCIENCES INC / KZR FAQ

What is the fundamental rating for KZR stock?

ChartMill assigns a fundamental rating of 2 / 10 to KZR.


What is the valuation status of KEZAR LIFE SCIENCES INC (KZR) stock?

ChartMill assigns a valuation rating of 0 / 10 to KEZAR LIFE SCIENCES INC (KZR). This can be considered as Overvalued.


What is the profitability of KZR stock?

KEZAR LIFE SCIENCES INC (KZR) has a profitability rating of 1 / 10.


How financially healthy is KEZAR LIFE SCIENCES INC?

The financial health rating of KEZAR LIFE SCIENCES INC (KZR) is 4 / 10.